Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

NCT00755534 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

68

Enrollment

OTHER

Sponsor class

Stopped Due to poor accrual

Conditions

Colorectal Cancer

Interventions

DRUG: Irinotecan
DRUG: Capecitabine
DRUG: Cetuximab
DRUG: Oxaliplatin

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]